Trial · NCT00986245
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Patient Preference | After 16 weeks or at last visit for early completion | Primary outcome measure was the preference of the subjects between once-daily versus twice-daily of RPR at the completion or at early completion after crossover.~61 of participants completing period with study intervention. | participants | NUMBER |
| SECONDARY | Unified Parkinson's Disease Rating Scale, Part 3 | 8 weeks for each arm or at last visit | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. Once-daily or Twice-daily arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | units on a scale | MEAN |
| SECONDARY | Hoehn and Yahr Stage | 8 weeks for each arm or at last visit | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. Once-daily or twice-daily arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | Scores on a scale | MEAN |
| SECONDARY | Overall Quality of Sleep | 8 weeks for each arm or at last visit | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | units on a scale | MEAN |
| SECONDARY | Nocturnal Off-symptoms | 8 weeks for each arm or at last visit | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | units on a scale | MEAN |
| SECONDARY | Early Morning Off Symptoms | 8 weeks for each arm or at last visit | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | units on a scale | MEAN |
| SECONDARY | Epworth Sleep Scale | 8 weeks in each arm or at last visit for early completion | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | units on a scale | MEAN |
| SECONDARY | Compliance | 8 weeks for each arm or at last visit | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | percentage of used medication | MEAN |
| SECONDARY | Adverse Events | After 8 weeks in each arm or at last visit for early completion | Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively. | participants | NUMBER |
| SECONDARY | Patients Who Have Global Impression for Improvement | After 8 weeks in each arm or at last visit for early completion | The number of patient who completed the study and answered the questionnaire for global impression. | participants | NUMBER |
| SECONDARY | Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation | After 8 weeks in each arm or at last visit for early completion | The number of patient who completed the study and answered the questionnaire for global impression to motor fluctuation duration. | participants | NUMBER |
| SECONDARY | Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation | After 8 weeks in each arm or at last visit for early completion | The number of patient who completed the study and answered the questionnaire for global impression to motor fluctuation severity. | participants | NUMBER |
| SECONDARY | Patients Who Have Global Impression for Improvement to Duration of Dyskinesia | After 8 weeks in each arm or at last visit for early completion | The number of patient who completed the study and answered the questionnaire for global impression to dyskinesia duration. | participants | NUMBER |
| SECONDARY | Patients Who Have Global Impression for Improvement to Severity of Dyskinesia | After 8 weeks in each arm or at last visit for early completion | The number of patient who completed the study and answered the questionnaire for global impression to dyskinesia severity. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00986245/outcomes